Join the 'Psoriatic Arthritis' group to help and get support from people like you.

Psoriatic Arthritis Blog

Drug Shows Promise Against Arthritis Common in People with Psoriasis

Posted 11 Jun 2014 by Drugs.com

WEDNESDAY, June 11, 2014 – A new drug called brodalumab appears to be effective in treating patients suffering from psoriatic arthritis, a study says. Patients who responded to brodalumab had a significant improvement in their skin and reduction in the swelling of the fingers and toes, a condition called dactylitis that is common in psoriatic arthritis, according to the study's lead researcher, Dr. Philip Mease, a rheumatologist at Swedish Medical Center in Seattle. "We have a medication with a different mechanism of action than currently available drugs, increasing our chances to control this disease, which can be disabling and significantly affects patients' function and quality of life," said Mease. "We know that many patients will lose response to some medications or develop adverse effects, so there is a need for medicines that work differently," he said. "We have a chance to ... Read more

Related support groups: Psoriatic Arthritis

Otezla Approved for Psoriatic Arthritis

Posted 23 Mar 2014 by Drugs.com

FRIDAY, March 21, 2014 – Otezla (apremilast) has been approved by the U.S. Food and Drug Administration to treat adults with active psoriatic arthritis, a condition associated with the autoimmune skin disease psoriasis. Most people develop psoriasis first and are subsequently diagnosed with psoriatic arthritis. Common symptoms of the latter are joint pain, stiffness and swelling. Otezla was evaluated in clinical studies involving nearly 1,500 people with active psoriatic arthritis. In a Friday news release, the FDA said Otezla users should be monitored carefully for unexplained weight loss or signs of depression. Pregnant women must register for the drug's use, the agency added. The most common side effects noted during clinical testing included diarrhea, nausea and headache. Otezla is produced for Celgene Corp., based in Summit, N.J. More information The FDA has more about this ... Read more

Related support groups: Psoriatic Arthritis

FDA Approves Otezla (apremilast) to Treat Psoriatic Arthritis

Posted 23 Mar 2014 by Drugs.com

March 21, 2014 – The U.S. Food and Drug Administration today approved Otezla (apremilast) to treat adults with active psoriatic arthritis (PsA). PsA is a form of arthritis that affects some people with psoriasis. Most people develop psoriasis first and are later diagnosed with PsA. Joint pain, stiffness and swelling are the main signs and symptoms of PsA. Currently approved treatments for PsA include corticosteroids, tumor necrosis factor (TNF) blockers, and an interleukin-12/interleukin-23 inhibitor. “Relief of pain and inflammation and improving physical function are important treatment goals for patients with active psoriatic arthritis,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “Otezla provides a new treatment option for patients suffering from this disease.” The safety and effective ... Read more

Related support groups: Psoriatic Arthritis

FDA Approves Cimzia for Treatment of Adult Patients with Active Psoriatic Arthritis

Posted 30 Sep 2013 by Drugs.com

BRUSSELS, Sept. 30, 2013 /PRNewswire/ - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA). "The FDA's approval of Cimzia for the treatment of active PsA provides an additional, effective treatment option for those living with the condition.  Psoriatic arthritis brings with it a heavy disease burden that often strikes during the prime years of life, impacting health-related quality of life and physical function," said Dr. Philip J. Mease, Director Rheumatology Research, Swedish Medical Center and Clinical Professor, University of Washington School of Medicine, Seattle, WA, U.S. "The RAPID™-PsA study supporting the US approval is the first randomized, controlled study of an anti-TNF in PsA  to include patients with and without prior anti-TNF exposure. The ... Read more

Related support groups: Psoriatic Arthritis, Cimzia, Certolizumab

Stelara (ustekinumab) Receives FDA Approval to Treat Active Psoriatic Arthritis

Posted 23 Sep 2013 by Drugs.com

HORSHAM, Pa., Sept. 23, 2013 /PRNewswire/ – Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. It is estimated that more than two million people in the U.S. are living with psoriatic arthritis1, a chronic autoimmune disease characterized by both joint inflammation and psoriasis skin lesions. "It is critical for dermatologists and rheumatologists to be able to offer new and novel treatment options to our adult patients living with psoriatic arthritis, a disease where additional biologic options are very much needed," said investigator and Steering Committee member Alice B. Gottlieb, triple board certified in dermatology, rheumatology and internal medicine, M.D., Ph.D, Chief and ... Read more

Related support groups: Psoriatic Arthritis, Stelara, Ustekinumab

Horizon Pharma Announces FDA Approval of Rayos (prednisone) Delayed-Release Tablets for Rheumatoid Arthritis and Multiple Additional Indications

Posted 31 Jul 2012 by Drugs.com

DEERFIELD, Ill., July 26, 2012 /PRNewswire/ – Horizon Pharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Rayos (prednisone) delayed-release tablets (1 mg, 2 mg and 5 mg) to treat a broad range of diseases including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma and chronic obstructive pulmonary disease (COPD). The FDA approval was supported by data bridging the pharmacokinetics of Rayos to immediate-release prednisone and data from the Circadian Administration of Prednisone in RA (CAPRA-1 and 2) trials. The CAPRA-2 trial demonstrated that people with moderate to severe RA treated with Rayos experienced a statistically significant improvement in ACR20 response criteria compared to placebo. The CAPRA-1 trial supported the overall safety of Rayos. "We are extremely pleased the ... Read more

Related support groups: Rheumatoid Arthritis, Prednisone, Asthma, Psoriatic Arthritis, Ankylosing Spondylitis, Polymyalgia Rheumatica, COPD

Gene Behind Psoriasis Identified, Researchers Say

Posted 19 Apr 2012 by Drugs.com

THURSDAY, April 19 – Scientists say they've identified the first gene directly linked to the most common form of psoriasis, known as plaque psoriasis. "We have searched for almost two decades to find a single gene linked to plaque psoriasis," study senior author Anne Bowcock, professor of genetics at Washington University School of Medicine in St. Louis, said in a university news release. "Individually, the rare mutations we have found likely confer a high risk for the disease, and we think they will be important in the search to find new, more effective treatments." In conducting the study, researchers used cutting-edge DNA technology to uncover a rare mutation in the CARD14 gene in a large family of European descent with a high prevalence of plaque psoriasis and psoriatic arthritis. They also found the mutation among multiple members of an extended family from Taiwan who had the ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis

Forgoing Medication, for Baby's Sake

Posted 6 Apr 2012 by Drugs.com

FRIDAY, April 6 – Laura Mokelke was diagnosed with painful psoriatic arthritis when she was just 19 years old. A powerful combination of medications helps to keep her symptoms at bay, including methotrexate, a drug that is used to treat certain types of cancer. Now 30, Mokelke and her husband would like to have a baby. Concerned about the potential effects her medications might have on a growing fetus, the Mokelkes followed her doctor's advice and have been working with her rheumatologist and obstetrician to adjust her medications. "My rheumatologist and gynecologist always told me that the consequences of getting pregnant while taking methotrexate would be devastating," said Mokelke. She said the doctors explained that she would probably miscarry on methotrexate, but that if she managed to carry a baby to term, the baby could very well have severe birth defects. "We were told that it ... Read more

Related support groups: Psoriatic Arthritis

Health Tip: Do You Have Psoriatic Arthritis?

Posted 1 Dec 2011 by Drugs.com

-- Psoriatic arthritis is an inflammatory joint condition that is associated with the chronic skin condition psoriasis. The Arthritis Foundation says common symptoms of psoriatic arthritis include: Joints that are swollen and painful. Pain and soreness where tendons attach to bone, such as at the heel. Pitting or separation of nails from the nail bed. Back pain. Conjunctivitis, characterized by redness and pain in tissues surrounding the eyes. Feeling fatigued, reduced range of motion in the joints and feeling stiff in the morning. Read more

Related support groups: Psoriatic Arthritis

1 in 4 With Psoriasis May Have Undiagnosed Arthritis

Posted 13 Oct 2011 by Drugs.com

THURSDAY, Oct. 13 – Nearly one in four Americans with the chronic skin condition known as psoriasis may also have undiagnosed psoriatic arthritis, according to a new study. This is in addition to the 2 million people in the United States who have been diagnosed with the disease, a type of inflammatory arthritis that affects the joints and tendons and can lead to joint destruction and disability. For the study, the National Psoriasis Foundation conducted phone and online interviews of 477 people with psoriasis and psoriatic arthritis. The investigators found that 22 percent of the participants who had been diagnosed with psoriasis-only had significant symptoms of psoriatic arthritis: joint pain, pain that shifts from one joint to the other, joints that felt hot to the touch and very swollen fingers and toes. Psoriasis is the most common autoimmune disease in the United States, affecting ... Read more

Related support groups: Psoriasis, Psoriatic Arthritis

Psoriatic Arthritis Patients Seem to Lack Enough Vitamin D

Posted 11 Jul 2011 by Drugs.com

MONDAY, July 11 – Vitamin D insufficiency is common among people with psoriatic arthritis, but levels of the vitamin in the blood do not affect disease activity, a new study finds. People with psoriatic arthritis have the chronic skin disorder psoriasis accompanied by inflammatory arthritis. The study, published in the July 11 issue of the journal Arthritis Care & Research, included more than 300 patients living in Toronto and Haifa, Israel, two geographically diverse locations. Vitamin D levels in the blood – known as 25-hydroxyvitamin D [25 (OH) D] – were measured in the summer and winter. Vitamin D is produced by the skin in response to exposure to sunlight. It is also found in certain foods, including eggs, fish and fortified foods such as dairy products and breakfast cereals. In the Canadian patients, 56 percent had insufficient 25 (OH) D levels during the winter and 59 percent ... Read more

Related support groups: Psoriatic Arthritis, Vitamin D Deficiency, Vitamin D Insufficiency

Obesity as Young Adult May Boost Psoriatic Arthritis Risk

Posted 19 Jul 2010 by Drugs.com

MONDAY, July 19 – People who are obese at age 18 are at increased risk of developing psoriatic arthritis, a new study suggests. Psoriatic arthritis is a type of arthritis that develops in the joints of 6 percent to 42 percent of people with psoriasis, a condition that causes itchy or sore patches of skin. The new study included 943 psoriasis patients who took part in the Utah Psoriasis Initiative from 2002 to 2008. Of those patients, 26.5 percent had psoriatic arthritis. The researchers found that predictors of psoriatic arthritis included body mass index (BMI, a ratio of weight to height) at age 18, younger age at psoriasis onset, being female, and having larger body surface areas affected by psoriasis. The earliest onset of psoriatic arthritis occurred in obese and overweight participants. Twenty percent of those who were overweight or obese at age 18 developed psoriatic arthritis by ... Read more

Related support groups: Obesity, Psoriatic Arthritis

Simponi Approved for Immune-Related Arthritis

Posted 24 Apr 2009 by Drugs.com

FRIDAY, April 24 – Simponi (golimumab) has been approved by the U.S. Food and Drug Administration to treat three forms of arthritis that occur when the body's immune system attacks the joints. The injected drug, administered once a month, was sanctioned to treat moderate-to-severe rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis, the agency said in a news release. It's among a class of drugs that target tumor necrosis factor-alpha (TNF-α). When overproduced, this protein can cause inflammation and damage to bones, cartilage, and tissue. As with similar medicines, Simponi's label will include a so-called "black-box" warning that users face an increased risk of tuberculosis and invasive fungal infections, the FDA said. Common side effects of the drug include upper respiratory tract infection, sore throat, and nasal congestion. Simponi is marketed by ... Read more

Related support groups: Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis

New Drug May Help Patients With Psoriatic Arthritis

Posted 9 Apr 2009 by Drugs.com

THURSDAY, April 9 – The drug golimumab shows promise in treating psoriatic arthritis, according to a new study. Psoriatic arthritis affects about 11 percent of people with psoriasis. The University of California, San Diego-led study included 405 patients who still had active psoriatic arthritis after taking anti-rheumatic drugs or nonsteroidal anti-inflammatory drugs. The patients were randomly selected to receive injections of either 50 or 100 milligrams of golimumab or placebo every four weeks for 24 weeks. The phase 3 study found that 51 percent of patients in the 50-mg group, 45 percent of those in the 100-mg group, and 9 percent of those in the placebo group achieved the American College of Rheumatology 20 percent improvement criteria (ACR20) by week 14. The improvements were in areas such as swollen and tender joints, pain, disease activity, physical function, and levels of ... Read more

Related support groups: Psoriatic Arthritis

Drug Reduces Inflammatory Arthritis Symptoms, Lesions

Posted 12 Feb 2009 by Drugs.com

THURSDAY, Feb. 12 – The drug ustekinumab shows promise against psoriatic arthritis (PA), according to a study that included patients from 24 sites in Europe and North America. PA affects about 11 percent of patients with psoriasis, an autoimmune disease that affects the skin and joints. Some patients don't respond to current drug treatments for PA, so researchers are trying to find alternative therapies, according to background information in a news release about the study. It's believed that interleukins 12 and 23 may play a role in PA. Interleukins are immune system-produced proteins that mediate inflammatory reactions in diseases such as psoriasis. Ustekinumab prevents interleukins 12 and 23 from binding to cell membranes. In this study, patients were randomly assigned to receive either: ustekinumab (90 milligrams or 63 milligrams) every week for four weeks, followed by placebo at ... Read more

Related support groups: Psoriatic Arthritis

Ask a Question

Further Information

Related Condition Support Groups

Spondyloarthritis

Related Drug Support Groups

prednisone, methotrexate, Humira, Enbrel, Remicade, cortisone, dexamethasone, triamcinolone, sulfasalazine, view more... cyclosporine, Decadron, Cimzia, leflunomide, Stelara, Simponi, azathioprine, hydroxyurea, mycophenolate mofetil, infliximab, Aristocort, Kenalog-40, Acthar, acitretin, etanercept, Acth, Deltasone, adalimumab, Acthar Gel, HP, ustekinumab, Otezla, Sterapred, golimumab, Liquid Pred, Sterapred DS, Methotrexate LPF Sodium, Adrenocot, Aristocort for Injection, Trexall, corticotropin, Rayos, Triamonide 40, Triam-A, Tristoject, Decaject, Baycadron, TAC 3, Kenaject-40, Triam-Forte, Tramacort-D, Clinalog, Ken-Jec 40, Dalalone, Solganal, Clinacort, U-Tri-Lone, Dexamethasone Intensol, Triamcot, Trilog, Trilone, Cort-K, Dexone, Hexadrol, Rheumatrex Dose Pack, Decadron-LA, Solurex LA, Solurex, Dexacen-4, Folex PFS, Ridaura, auranofin, alefacept, aurothioglucose, certolizumab, apremilast, De-Sone LA, Dexacort-LA, Dexpak Taperpak, Medidex LA, Meticorten, Orasone, Prednicot, Prednicen-M, Medidex, Dexacorten, Dexasone LA, Dexasone, abatacept, Dexone LA, Primethasone, Cortone Acetate